Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MRKR Stock Summary
Top 10 Correlated ETFs
MRKR
In the News
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
Why Is Marker Therapeutics (MRKR) Stock Up 27% Today?
Marker Therapeutics (NASDAQ: MRKR ) stock is rising higher on Wednesday as investors react to positive pre-clinical news from the clinical-stage immuno-oncology company. Today's results come from a test of MT-601 in lymphoma cells.
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
More low float penny stocks to watch. The post 7 Low Float Penny Stocks To Watch After SNTG Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022.
3 Hot Penny Stocks To Buy For Under $1 Right Now
If you're watching the action in the stock market today, you're seeing plenty of chop. The U.S. dollar's strength has pushed broader markets lower, but a mix of positive and negative economic against this week's PPI data and CPI data has brought much more push-pull action.
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Anthony H. Kim, Chief Financial Officer of Marker Therapeutics, will present at two upcoming investor conferences in March.
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting.
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MRKR Financial details
MRKR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.11 | 0.05 | 0.1 | 0.16 | 1.08 | |
Net income per share | -77.5 | -4.46 | -6.06 | -5.47 | -3.58 | |
Operating cash flow per share | -7.58 | -4.01 | -4.01 | -3.57 | -3.23 | |
Free cash flow per share | -7.66 | -4.09 | -6.23 | -3.97 | -3.82 | |
Cash per share | 32.34 | 9.63 | 4.54 | 5.54 | 1.41 | |
Book value per share | 31.08 | 9.67 | 5.81 | 5.75 | 2.35 | |
Tangible book value per share | 31.08 | 9.67 | 5.81 | 5.75 | 2.35 | |
Share holders equity per share | 31.08 | 9.67 | 5.81 | 5.75 | 2.35 | |
Interest debt per share | 0 | 0.11 | 2.61 | 1.55 | 0.91 | |
Market cap | 105.96M | 131.29M | 68.21M | 72.7M | 22.21M | |
Enterprise value | 44.21M | 87.87M | 59.11M | 42.21M | 18.04M | |
P/E ratio | -0.72 | -6.46 | -2.39 | -1.74 | -0.74 | |
Price to sales ratio | 514.38 | 615.84 | 146.12 | 58.54 | 2.47 | |
POCF ratio | -7.32 | -7.18 | -3.62 | -2.66 | -0.82 | |
PFCF ratio | -7.24 | -7.04 | -2.33 | -2.39 | -0.7 | |
P/B Ratio | 1.79 | 2.98 | 2.49 | 1.65 | 1.13 | |
PTB ratio | 1.79 | 2.98 | 2.49 | 1.65 | 1.13 | |
EV to sales | 214.63 | 412.17 | 126.64 | 34 | 2 | |
Enterprise value over EBITDA | -0.3 | -3.95 | -2.12 | -1.16 | -0.69 | |
EV to operating cash flow | -3.05 | -4.81 | -3.13 | -1.55 | -0.67 | |
EV to free cash flow | -3.02 | -4.71 | -2.02 | -1.39 | -0.57 | |
Earnings yield | -1.4 | -0.15 | -0.42 | -0.58 | -1.35 | |
Free cash flow yield | -0.14 | -0.14 | -0.43 | -0.42 | -1.44 | |
Debt to equity | 0 | 0.01 | 0.45 | 0.27 | 0.39 | |
Debt to assets | 0 | 0.01 | 0.27 | 0.17 | 0.22 | |
Net debt to EBITDA | 0.42 | 1.95 | 0.33 | 0.84 | 0.16 | |
Current ratio | 22.11 | 22.83 | 3.81 | 3.56 | 2.14 | |
Interest coverage | 0 | 0 | 0 | 0 | 1.98K | |
Income quality | 0.1 | 0.85 | 0.66 | 0.65 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 118.35 | 46.8 | 22.43 | 10.41 | 1.42 | |
Research and developement to revenue | 601.95 | 59.87 | 40.45 | 22.38 | 2.9 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.55 | 0.11 | 0.18 | |
Capex to revenue | -0.72 | -1.76 | -22.34 | -2.52 | -0.55 | |
Capex to depreciation | 0 | -1.31 | -9.69 | -0.99 | -1.34 | |
Stock based compensation to revenue | 79.37 | 25.13 | 11.2 | 4.8 | 0.59 | |
Graham number | 232.8 | 31.15 | 28.16 | 26.61 | 13.75 | |
ROIC | -2.49 | -0.47 | -0.55 | -0.58 | -0.86 | |
Return on tangible assets | -2.38 | -0.44 | -0.63 | -0.61 | -0.87 | |
Graham Net | 30.92 | 9.14 | 0.71 | 2.38 | -0.15 | |
Working capital | 59.19M | 43.49M | 18.01M | 33.08M | 8.84M | |
Tangible asset value | 59.34M | 44.09M | 27.34M | 43.99M | 19.6M | |
Net current asset value | 59.19M | 43.21M | 6.14M | 21.83M | 1.8M | |
Invested capital | 0 | 0.01 | 0.45 | 0.27 | 0.39 | |
Average receivables | 54.09K | 82.18K | 528.37K | 500.4K | 1.2M | |
Average payables | 1.32M | 1.31M | 1.96M | 4.04M | 3.38M | |
Average inventory | 0 | 0 | -500K | -500K | 0 | |
Days sales outstanding | 191.68 | 96.2 | 782.38 | 0.07 | 97.37 | |
Days payables outstanding | 0 | 28.39 | 56.74 | 593.67 | 159.87 | |
Days of inventory on hand | 0 | 0 | -19.33 | 0 | 0 | |
Receivables turnover | 1.9 | 3.79 | 0.47 | 5.24K | 3.75 | |
Payables turnover | 0 | 12.85 | 6.43 | 0.61 | 2.28 | |
Inventory turnover | 0 | 0 | -18.88 | 0 | 0 | |
ROE | -2.49 | -0.46 | -1.04 | -0.95 | -1.53 | |
Capex per share | -0.08 | -0.08 | -2.22 | -0.41 | -0.59 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.35 | 0.72 | 0.4 | 0.09 | 0.03 | |
Net income per share | -0.82 | -0.48 | -0.56 | 0.29 | -0.34 | |
Operating cash flow per share | -0.91 | -0.75 | -0.68 | -0.81 | -0.13 | |
Free cash flow per share | -0.93 | -0.77 | -0.69 | -0.8 | -0.13 | |
Cash per share | 2.16 | 1.41 | 0.73 | 2.08 | 1.98 | |
Book value per share | 2.7 | 2.34 | 1.82 | 2.18 | 1.89 | |
Tangible book value per share | 2.7 | 2.34 | 1.82 | 2.18 | 1.89 | |
Share holders equity per share | 2.7 | 2.34 | 1.82 | 2.18 | 1.89 | |
Interest debt per share | 0.93 | 0.89 | 0.85 | 0 | -0.26 | |
Market cap | 30.83M | 22.27M | 6.19M | 27.04M | 40.07M | |
Enterprise value | 20.47M | 18.1M | 7.28M | 8.91M | 22.6M | |
P/E ratio | -1.13 | -1.39 | -0.32 | 2.69 | -3.36 | |
Price to sales ratio | 10.45 | 3.68 | 1.77 | 35.45 | 155.55 | |
POCF ratio | -4.03 | -3.53 | -1.05 | -3.83 | -35.54 | |
PFCF ratio | -3.98 | -3.46 | -1.03 | -3.89 | -35.54 | |
P/B Ratio | 1.36 | 1.14 | 0.39 | 1.42 | 2.4 | |
PTB ratio | 1.36 | 1.14 | 0.39 | 1.42 | 2.4 | |
EV to sales | 6.94 | 2.99 | 2.08 | 11.69 | 87.71 | |
Enterprise value over EBITDA | -3.42 | -6.27 | -1.78 | -2.16 | -7.06 | |
EV to operating cash flow | -2.68 | -2.87 | -1.24 | -1.26 | -20.04 | |
EV to free cash flow | -2.64 | -2.81 | -1.21 | -1.28 | -20.04 | |
Earnings yield | -0.22 | -0.18 | -0.79 | 0.09 | -0.07 | |
Free cash flow yield | -0.25 | -0.29 | -0.97 | -0.26 | -0.03 | |
Debt to equity | 0.34 | 0.39 | 0.47 | 0 | -0.14 | |
Debt to assets | 0.19 | 0.22 | 0.27 | 0 | -0.12 | |
Net debt to EBITDA | 1.73 | 1.44 | -0.27 | 4.38 | 5.46 | |
Current ratio | 1.99 | 2.14 | 2.1 | 7.52 | 7.01 | |
Interest coverage | -70.37 | 27.78 | 60.15 | 0 | 0 | |
Income quality | 1.1 | 1.64 | 1.19 | 2.1 | 0.38 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.25 | 0.31 | 0.72 | 3.3 | 5.48 | |
Research and developement to revenue | 2.47 | 0.87 | 2.08 | 3.12 | 7.94 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.02 | -0.02 | 0 | |
Capex to revenue | -0.03 | -0.02 | -0.03 | 0.15 | 0 | |
Capex to depreciation | -0.1 | -0.13 | -0.12 | 0 | 0 | |
Stock based compensation to revenue | 0.51 | 0.12 | 0.19 | -0.16 | 0.68 | |
Graham number | 7.04 | 5.01 | 4.79 | 3.76 | 3.79 | |
ROIC | -0.18 | -0.11 | -0.16 | 0.03 | -0.22 | |
Return on tangible assets | -0.17 | -0.12 | -0.17 | 0.11 | -0.15 | |
Graham Net | 0.1 | -0.15 | -0.52 | 1.89 | 1.67 | |
Working capital | 11.14M | 8.84M | 5.71M | 19.03M | 16.71M | |
Tangible asset value | 22.6M | 19.6M | 15.91M | 19.03M | 16.71M | |
Net current asset value | 3.91M | 1.8M | -1.11M | 19.03M | 16.71M | |
Invested capital | 0.34 | 0.39 | 0.47 | 0 | -0.14 | |
Average receivables | 1.15M | 2.04M | 2.24M | 1.91M | 914.71K | |
Average payables | 1.89M | 1.82M | 2.24M | 2.23M | 1.95M | |
Average inventory | 0 | 0 | -500K | -500K | 0 | |
Days sales outstanding | 51.29 | 35.71 | 53.56 | 206.05 | 29.11 | |
Days payables outstanding | 174.51 | 150.34 | 76.31 | 60.19 | 0 | |
Days of inventory on hand | 0 | 0 | -26.65 | 0 | 0 | |
Receivables turnover | 1.75 | 2.52 | 1.68 | 0.44 | 3.09 | |
Payables turnover | 0.52 | 0.6 | 1.18 | 1.5 | 0 | |
Inventory turnover | 0 | 0 | -3.38 | 0 | 0 | |
ROE | -0.3 | -0.2 | -0.31 | 0.13 | -0.18 | |
Capex per share | -0.01 | -0.02 | -0.01 | 0.01 | 0 |
MRKR Frequently Asked Questions
What is Marker Therapeutics, Inc. stock symbol ?
Marker Therapeutics, Inc. is a US stock , located in Houston of Tx and trading under the symbol MRKR
What is Marker Therapeutics, Inc. stock quote today ?
Marker Therapeutics, Inc. stock price is $4.34 today.
Is Marker Therapeutics, Inc. stock public?
Yes, Marker Therapeutics, Inc. is a publicly traded company.